Chiron Real Estate, Inc. (XRN)
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-09
$36.98-0.51%
Close 2026-09-09 · 1-day change
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Chiron bought a senior housing community for $130 million. It raised $100 million by selling preferred stock. The company aims for Core FFO per share near $4.38 in 2026. These moves support growth and cash flow recovery.
Chiron is still losing money and cut its dividend by 36%. Earnings estimates have fallen sharply. The company faces volatile management and sector headwinds. These risks could hurt its turnaround.
The price is about 20% below our fair value near $47. Analysts expect about 2% revenue growth. Our fair value is above the Street median near $40.
Breaks if: Acquisition not completed or cost deviates materially from $130 million
Breaks if: Core FFO per share falls below $4.30 in 2026
Preferred stock issuance falls short of 1,000,000 shares or $100 million
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity with a focus on growth through strategic acquisitions. The current thesis state reflects a medium confidence level, as recent changes have not yet provided enough financial performance history to fully assess the investment outlook.
The market appears to price XRN as a cheap option compared to its peers, with a slight expectations gap. The valuation suggests that investors may be cautious but see potential in the company's strategy.
Fundamentals are likely to improve as management executes its priorities, particularly in expanding the portfolio and capital allocation. However, there is a near-term risk of missing earnings estimates, which could impact investor sentiment.
The long-term thesis hinges on several factors, including the Fed's interest rate decisions and performance of sector bellwethers. Additionally, management's ability to execute on their growth strategy and navigate potential earnings misses will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, XRN's performance will depend on effective management execution and external economic factors. Not investment advice.